Keymen Pharmaceuticals established in 1973 with Keymen Ecza Depoculuk ve Ticaret Ltd. Sti. name and operates under DMT Group.
Foundation of DMT group began with the establishment of Dr.Mustafa Topal’s first personal firm in 1965 and with establishment of Ecz.Perihan Topal Import-Export-Representation firm in 1970. Starting inn 1966, the firm handled the importation & distribution of special medicines of Dr.Anna Arslan from Romaina and medical equipment from USSR. During visits to East European countries, Dr.Mustafa Topal saw that high attention was given to public health services, and that products for public health in this region were very cheap. After investigating public health products further, Keyman began to cooperate with the Institute of Immunology and Virology Torlak in Belgrade, Serbia, and the Institute of Immunology Inc in Zagreb, Croatia, for the sales of vaccines and antisera in Turkey, collaboration that continue today.
Contact Details
Keymen İlaç Sanayi ve Ticaret A.Ş.
Şehit Gaffar Okkan Cad. No: 40
Gölbaşı 06830 ANKARA
Tel: 0 312 485 37 60
Fax: 0 312485 37 61
Keymen İlaç Sanayi ve Ticaret A.Ş.
Çamlık Mah. İkbal Cad. Dinç Sok. No:25
Ümraniye İSTANBUL
Tel: 0216 415 03 30
Fax: 0 216 415 03 27
Keyman’s general manager discusses his firm’s development efforts towards vaccine production, in conjunction with TUBITAK and Hacettepe University, and their geographic expansion into Africa, Latin America, and Southeast Asia. Please…
A recent arrival from China, Lilly’s Turkey MD Daniel Lucas assesses the country’s healthcare system and raises key questions about the sustainability of the system at large going forward, and…
MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy…
GSK’s VP and Area GM Pharmaceuticals, Turkey and Caucasus, and chairman of Turkey’s innovative pharmaceutical association, discusses the effectiveness of the government’s current strategy for reducing the trade deficit in…
Imuneks is currently operating in the OTC market, but with three supergeneric products ready to market on the RX side, the firm has the potential to soon become one of…
Recordati’s South East regional VP, based in Istanbul, discusses Recordati Turkey’s key role as a manufacturing hub for Recordati, the importance of the Turkish market (fourth largest globally for the…
Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government…
Biocodex’s new general manager gives an overview of the affiliates ‘new deal’ program, and how the company has adjusted its approach to better fit the contemporary Turkish environment. What attracted…
The general manager of Daiichi Sankyo Turkey discusses his affiliate’s expansion into a regional hub, current strategies for growth in the Turkish market, and the keys behind his affiliates multiple ‘great…
Turkey’s leading pharmaceutical company is in the process of developing production facilities abroad, and it has just begun construction of a USD 100 million biotech facility; CEO Süha Taşpolatoğlu believes…
The leadership of Turkey’s newest major pharmaceutical player, Pharmactive, discuss the firm’s two pronged growth strategy, detailing their own sales objectives and prospects, as well as the opportunities that they…
Polifarma is Turkey’s largest producer of basic parenteral IV solutions with a 41 percent market share the country and growing exports across the region. According to the Chairman and CEO…
See our Cookie Privacy Policy Here
